Report Content
Chapter 1 Methodology
1.1 Methodology
1.2 Market scope & definitions
1.3 Base estimates & working
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data sources
1.7.1 Primary
1.7.2 Secondary
1.7.2.1 Paid sources
1.7.2.2 Public sources
Chapter 2 Executive Summary
2.1 Clinical trials industry 3600 synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Phases trends
2.1.3 Study design trends
2.1.4 Therapeutic area trends
2.1.5 Regional trends
Chapter 3 Clinical trials Industry Insights
3.1 Industry segentation
3.2 Industry landscape, 2018 – 2032
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Increasing prevalence of chronic diseases across the globe
3.3.1.2 Growing demand for outsourcing clinical trials to CROs
3.3.1.3 Rise in government and non-government funding for clinical trials
3.3.1.4 Growing opportunities for conducting clinical trials in countries of Asia Pacific
3.3.2 Industry pitfalls & challenges
3.3.2.1 Lack of skilled workforce in clinical research
3.3.2.2 Infrastructural barriers in developing countries
3.3.2.3 Challenges faced in North America & Europe for conducting clinical trials
3.4 Growth potential analysis
3.4.1 By phases
3.4.2 By study design
3.4.3 By therapeutic area
3.5 COVID-19 impact analysis
3.6 Clinical trials volume analysis
3.6.1 Clinical trials volume analysis, by region, 2018-2022
3.6.2 Clinical trials volume analysis, by phase of development, 2018-2022
3.6.3 Clinical trials volume analysis, by indication, 2018-2022
3.7 Regulatory landscape
3.7.1 U.S.
3.7.2 Europe
3.7.3 Asia Pacific
3.7.3.1 Singapore
3.7.3.2 Malaysia
3.7.3.3 Indonesia
3.7.3.4 Thailand
3.7.3.5 South Korea
3.7.3.6 Philippines
3.8 Clinical trials - Asia Pacific advantage
3.9 Porter’s analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Strategic dashboard, 2022
4.4 Merger & Acquisition landscape
4.5 Competitive analysis of major market players
4.6 Competitive positioning matrix
4.7 Strategic outlook matrix
Chapter 5 Clinical Trials Market, By Phases
5.1 Key phases trends
5.2 Phase I
5.2.1 Market estimates and forecast, 2018 - 2032 (USD Milion)
5.3 Phase II
5.3.1 Market estimates and forecast, 2018 - 2032 (USD Milion)
5.4 Phase III
5.4.1 Market estimates and forecast, 2018 - 2032 (USD Milion)
5.5 Phase IV
5.5.1 Market estimates and forecast, 2018 - 2032 (USD Milion)
Chapter 6 Clinical Trials Market, By Study Design
6.1 Key study design trends
6.2 Interventional study
6.2.1 Market size, by region, 2017 - 2030 USD Milion)
6.3 Observational study
6.3.1 Market estimates and forecast, 2018 - 2032 (USD Milion)
6.4 Expanded access study
6.4.1 Market estimates and forecast, 2018 - 2032 (USD Milion)
Chapter 7 Clinical Trials Market, By Therapeutic Area
7.1 Key therapeutic area trends
7.2 Autoimmune disease
7.2.1 Market estimates and forecast, 2018 - 2032 (USD Milion)
7.3 Oncology
7.3.1 Market estimates and forecast, 2018 - 2032 (USD Milion)
7.4 Cardiology
7.4.1 Market estimates and forecast, 2018 - 2032 (USD Milion)
7.5 Infectious disease
7.5.1 Market estimates and forecast, 2018 - 2032 (USD Milion)
7.6 Dermatology
7.6.1 Market estimates and forecast, 2018 - 2032 (USD Milion)
7.7 Ophthalmology
7.7.1 Market estimates and forecast, 2018 - 2032 (USD Milion)
7.8 Others
7.8.1 Market estimates and forecast, 2018 - 2032 (USD Milion)
Chapter 8 Clinical trials Market, By Region
8.1 Key regional trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Russia
8.3.7 Poland
8.3.8 Switzerland
8.3.9 Netherlands
8.3.10 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Indonesia
8.4.7 Thailand
8.4.8 Singapore
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Colombia
8.5.5 Peru
8.5.6 Rest of Latin America
8.6 MEA
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Iraq
8.6.5 Israel
8.6.6 Rest of Middle East & Africa
Chapter 9 Company Profiles
9.1 Thermo Fisher Scientific (PPD, Inc)
9.2 Charles River Laboratories (MPI Research)
9.3 Clinipace Inc
9.4 ICON plc
9.5 IQVIA
9.6 Laboratory Corporation of America Holding (Covance Inc)
9.7 Medpace
9.8 Parexel International Corporation
9.9 Syneos health
9.10 The Emmes Company, LLC
9.11 WuXi AppTec
